Innonafactor®

INN Nonacog alfa

Recombinant activated coagulation factor IX, which is required for the treatment of haemophilia B.

Innonafactor was launched onto the Russian market in 2014.

GENERIUM is the only company in the world, which manufactures three recombinant coagulation factors (FVII, FVII and FIX) for the treatment of hemophilia A and B, including its inhibitor form.